Collegium Pharmaceutical (COLL) Q4 2023 earnings summary

Executive summary

• FY 2023 record net product revenue of $566.8M, up 22% YoY, and adjusted EBITDA of $367.0M, up 38% YoY; GAAP net income was $48.2M.

• 2024 priorities include operational execution, record revenue, adjusted EBITDA and net income, rapid debt repayment, and disciplined shareholder returns.

Financial highlights

• Q4 2023 net product revenue was $149.7M, up 16% YoY; FY revenue was $566.8M, up 22%.

• Q4 GAAP net income was $31.9M versus a $7.2M loss; FY GAAP net income was $48.2M versus a $25.0M loss in 2022.

• Q4 adjusted EBITDA was $104.2M, up 36% YoY; FY adjusted EBITDA was $367.0M, up 38%.

• Q4 GAAP operating expenses fell 13% YoY to $32.9M; FY GAAP operating expenses fell 10% to $159.2M. FY adjusted operating expenses were $123.6M, up 1%.

• FY adjusted net income was $223.3M versus $152.7M; adjusted diluted EPS was $5.47 versus $3.96.

Outlook and guidance

• FY 2024 net product revenue guidance is $580M–$595M; midpoint growth is 3.7% YoY.

• FY 2024 adjusted EBITDA guidance is $380M–$395M, excluding stock-based compensation; midpoint growth is 5.6% YoY.

• FY 2024 adjusted operating expense guidance is $120M–$125M, excluding stock-based compensation; midpoint is down 0.9% YoY.

• 2024 growth is expected to be fueled by Belbuca and Xtampza ER; Xtampza ER gross-to-net is expected to improve to 56%–58% following contract renegotiations.